GEN Exclusives

More »
New Products

Related to Mammalian Transient Transfection System

    • Growth Media for Bacterial Culture
    • BioSilta
    • EnPresso® B, a set of reagent-based growth systems for bacterial cultures, is designed to increase protein yields and improve the functionality of recombinant proteins. The products in the set are EnPresso B, EnPresso B Animal-free, and EnPres
    • Rocker Platform for Upstream Cell Culture
    • Finesse
    • The SmartRocker/SmartBag platform is designed for R&D and cGMP scale-up of cell growth processes. SmartBag, a bioprocess container, can be retrofitted for use with most rocker platform trays, or it may be used with the SmartRocker. The SmartRoc
    • ES/iPS Medium
    • EMD Millipore
    • PluriSTEM™ human ES/iPS medium is used for the expansion of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells in feeder- and serum-free conditions. The formulation includes Activin-A, TGFβ1, and b-FGF to promote stem cell sel
    • Chemically Defined Cell Culture Medium
    • EMD Millipore
    • Cellvento™ CHO-200 medium and complementary feeds are designed for fed-batch processes using CHO-S cell types expressing monoclonal antibodies. The formulation is meant to support high cell density growth and extended culture duration as well as lo
    • Agar and Membrane Transfer System
    • Sartorius Stedim Biotech
    • Microsart @media, agar media dishes for microbial limits testing, are prepared to satisfy U.S. Pharmacopeia (Chapter ) and European Pharmacopeia (Chapter 2.6.12) requirements. They are prefilled with various agar media types, such as tryptic soy ag
  • Page 1 of 1 (6 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?